Heartflow Q2 Loss Widens Despite 48% Jump In Revenue, Lifts FY26 Outlook
Heartflow (HTFL) reported Q2 revenue of $64.1M, up 48% year over year, driven by higher U.S. FFRCT and Plaque case volumes. Gross margin rose to 83.0%. Net operating loss widened to $17.9M. The company raised FY26 revenue guidance to $246M-$250M and adjusted gross margin to about 82%.
How this was made
The 30-second read
Why it matters
Traders can update models using the raised FY26 revenue range and adjusted gross margin outlook, while also reassessing near-term profitability risk given the wider net operating loss.
Market read
A guidance raise with improved adjusted gross margin outlook is the main bullish input, but the wider GAAP operating loss adds downside risk and can drive volatility.
What to watch
Non-GAAP operating loss narrowed while GAAP net loss per share worsened, suggesting investors may focus on cash burn and opex drivers not fully detailed here.
Background
Heartflow is an AI healthcare company focused on diagnosing and managing coronary artery disease, including FFRCT and Plaque workflows.
Ticker impact
Heartflow reported Q2 revenue up 48% to $64.1M but widened net operating loss to $17.9M and raised FY26 revenue guidance to $246M-$250M.
Near-term volatility likely as investors weigh raised revenue/margin targets against the operating expense surge.
The article provides both a positive forward-looking update (revenue and adjusted gross margin guidance) and a negative contemporaneous datapoint (wider net operating loss), which typically drives two-sided positioning.
Market effects
AI-enabled cardiology diagnostics names may see read-across interest if investors reward guidance and gross margin trajectory despite near-term opex pressure.
No specific regional catalyst beyond US-listed healthcare sentiment.
Limited; story is company-specific with no stated global regulatory or competitive shock.
Counterpoint
The raised revenue guidance could be achieved by scaling costs faster than expected, so the loss widening may persist even with improved gross margin.
Key entities
- companyHeartflow, Inc.
Reported Q2 2026 results, raised FY26 revenue guidance, and updated adjusted gross margin outlook.
- business segmentFFRCT
Heartflow’s FFRCT case volumes were cited as a key driver of Q2 revenue growth.
- business segmentPlaque business
Cited as an emerging second growth engine supporting physician utilization and adoption.
